{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:41:15Z","timestamp":1777354875512,"version":"3.51.4"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As breast cancer treatment advances, therapeutic efficacy has improved significantly, but cardiovascular toxicity from anticancer agents has become a critical concern. Elderly patients often have pre-existing cardiovascular comorbidities like coronary heart disease (CHD) and high venous thromboembolism (VTE) risk, requiring long-term antithrombotic therapy. Perioperative management demands individualized assessment of thrombotic and bleeding risks, with bridging anticoagulation when necessary. Close surveillance for cardiovascular complications (myocardial injury, heart failure, hypertension [HTN]) and control of modifiable risk factors (HTN, diabetes mellitus [DM]) are essential during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>This study presents a breast cancer patient with multiple cardiovascular comorbidities (HTN, DM, CHD). Following multidisciplinary team (MDT) consultation, the low-cardiotoxicity PTD regimen (pertuzumab, trastuzumab, docetaxel) was selected. Perioperatively, aspirin was withheld, and low-molecular-weight heparin (LMWH) bridging was used 24\u2005h before and after radical mastectomy. Postoperative radiotherapy was administered, with regular cardiac function monitoring throughout treatment. No cardiovascular complications occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For cancer patients with cardiovascular comorbidities, balancing tumor treatment and cardiovascular safety is achievable through comprehensive baseline risk assessment, the selection of low-cardiotoxicity regimens, rational perioperative antithrombotic adjustments, and continuous cardiac monitoring, thereby ensuring optimal oncological outcomes with minimized cardiovascular risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1690244","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:55:55Z","timestamp":1777352155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case analysis of antitumor therapy and cardiovascular safety management in a breast cancer patient with multiple cardiovascular diseases"],"prefix":"10.3389","volume":"13","author":[{"given":"Minghui","family":"Long","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boni","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B2","first-page":"289","article-title":"2023 Chinese expert consensus on perioperative cardiovascular risk assessment and management of non cardiac surgery in older patients national center of gerontology, cardiovascular geriatrics group of Chinese society of cardiology, editorial board of Chinese journal of geriatrics, editorial board of Chinese journal of cardiovascular medicine","volume":"29","author":"Xue","year":"2024","journal-title":"Chin J Cardiovasc Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0735-1097(23)01229-9","article-title":"Duration of dual antiplatelet therapy in patients post-pci using the precise-dapt score: insights from the singcloud database","volume":"81","author":"Fong","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.55503\/2790-6744.1211","article-title":"The utility of HAS-BLED score in predicting the bleeding risk of atrial fibrillation patients undergoing percutaneous coronary intervention receiving anticoagulation and dual anti-platelet therapy: a single center retrospective cohort study","volume":"29","author":"Adrian","year":"2022","journal-title":"JHKCC"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European Society of Cardiology in collaboration with the international cardio-oncology society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4081\/monaldi.2020.1348","article-title":"Cardio-oncology: the new frontier of clinical and preventive cardiology","volume":"90","author":"Paris","year":"2020","journal-title":"Monaldi Arch Chest Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","article-title":"Fluoropyrimidine-associated cardiotoxicity","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol Clin"},{"key":"B9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1253\/circrep.CR-25-0036","article-title":"Cancer therapy-related cardiac dysfunction in patients with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab and pertuzumab","volume":"7","author":"Ozaki","year":"2025","journal-title":"Circ Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e018393","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin exposure and risk of heart failure after anthracyclineor trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study","volume":"10","author":"Abdel-Qadir","year":"2021","journal-title":"J Am HeartAssoc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1479983","DOI":"10.3389\/fphar.2024.1479983","article-title":"Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1690244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:55:58Z","timestamp":1777352158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1690244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":13,"alternative-id":["10.3389\/fcvm.2026.1690244"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1690244","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1690244"}}